California’s AMT is latest biotech aiming to go public in pandemic IPO crazeCalifornia’s Applied Molecular Transport has become the latest biotech to go for an IPO during the pandemic, aiming Share XCalifornia’s AMT is latest biotech aiming to go public in pandemic IPO crazehttps://pharmaphorum.com/news/californias-amt/
Janssen trials ultrasound-guided approach to treating Crohn’sIn the highly competitive market for inflammatory diseases such as Crohn’s, pharma companies are looking for ways to Share XJanssen trials ultrasound-guided approach to treating Crohn’shttps://pharmaphorum.com/news/janssen-trials-ultrasound-guided-approach-to-treating-crohns/
Sosei Heptares bags another big partnership, this time with TakedaJapanese biotech Sosei’s buyout of the UK’s Heptares four years ago has rewarded it with a string of Share XSosei Heptares bags another big partnership, this time with Takedahttps://pharmaphorum.com/news/sosei-heptares-bags-another-big-partnership-this-time-with-takeda/
Drugs could mimic gut bacteria benefits to treat diabetesIt may be possible to design drugs that mimic the positive health benefits of gut bacteria to treat Share XDrugs could mimic gut bacteria benefits to treat diabeteshttps://pharmaphorum.com/news/drugs-gut-bacteria-diabetes/
AZ joins with Seres to research role of gut microbiome in cancerAstraZeneca has announced an immuno-oncology collaboration with US biotech Seres Therapeutics, which will focus on increasing understanding of Share XAZ joins with Seres to research role of gut microbiome in cancerhttps://pharmaphorum.com/news/az-joins-with-seres-to-research-role-of-gut-microbiome-in-cancer/
FDA advisers back Shire constipation drugShire’s constipation drug prucalopride is moving closer to market – advisers to the FDA have just unanimously backed Share XFDA advisers back Shire constipation drughttps://pharmaphorum.com/news/fda-advisers-back-shire-constipation-drug/
Pfizer eyes gastro use for Xeljanz after thumbs-up from FDA advisersPfizer has been steadily building a franchise around its inflammatory diseases pill, Xeljanz (tofacitinib) over the last few Share XPfizer eyes gastro use for Xeljanz after thumbs-up from FDA advisershttps://pharmaphorum.com/news/pfizer-eyes-gastro-use-xeljanz-thumbs-fda-advisers/
EU approval for Crohn’s another boost for fast-growing StelaraJ&J unit’s blockbuster gets new use. Share XEU approval for Crohn’s another boost for fast-growing Stelarahttps://pharmaphorum.com/news/janssens-stelara-approved-eu-crohns/
Alkermes closing in on Biogen with MS rivalALKS 8700 may have fewer side effects than Tecfidera. Share XAlkermes closing in on Biogen with MS rivalhttps://pharmaphorum.com/news/alkermes-closing-biogen-ms-challenger/